Ocumetics Technology Announces $2.5 Million Private Placement
November 26, 2025 — Leads & Copy —
Calgary, AB – Ocumetics Technology Corp. (TSXV: OTC) has announced a brokered private placement agreement with Centurion One Capital Corp., the lead agent and sole bookrunner, to raise up to $2.5 million. The offering involves the sale of up to 3,472,222 units at $0.72 each, with each unit comprising one common share and one common share purchase warrant.
Each warrant allows the holder to acquire one common share at $0.90 for three years after the closing date. Ocumetics has also granted the Lead Agent an option to sell an additional 520,833 units at the offering price, potentially generating another $375,000.
The proceeds from the offering will fund the company’s first-in-human clinical trials, ongoing research and development, and general corporate needs. The allocation of funds may shift based on future operations and opportunities. The units are offered privately under specific exemptions in British Columbia, Alberta, and Ontario, as well as in the United States and other agreed-upon international jurisdictions.
Securities issued under the Listed Issuer Financing Exemption are not subject to a statutory hold period. The public can access the offering document on SEDAR+ and Ocumetics’ website. The offering, pending regulatory and TSX Venture Exchange approvals, is expected to close around December 11, 2025. Insiders may participate in the offering, but their involvement is expected to remain below 25% of the company’s market capitalization, thus exempting it from certain requirements.
Ocumetics, a Canadian research and product development company, focuses on advanced vision correction solutions. Their primary objective is to improve patient quality of life. Ocumetics is currently in preclinical studies for an intraocular lens designed to eliminate the necessity for corrective lenses.
This intraocular lens is crafted to fit within the eye’s natural lens compartment and allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.
Mr. Dean Burns
President and CEO
Tel: 817-874-7564
Source: Ocumetics Technology Corp.
Share this story:
